AstraZeneca Inks $2.7B Deal For ZS Pharma
AstraZeneca said Friday that it had struck a deal to boost its portfolio of treatments for cardiovascular and metabolic diseases, agreeing to buy clinical-stage biopharmaceutical company ZS Pharma for $2.7 billion...To view the full article, register now.
Already a subscriber? Click here to view full article